Literature DB >> 9629566

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

M Masellis1, V Basile, H Y Meltzer, J A Lieberman, S Sevy, F M Macciardi, P Cola, A Howard, F Badri, M M Nöthen, W Kalow, J L Kennedy.   

Abstract

Using a pharmacogenetic approach in 185 schizophrenics who have been prospectively assessed for clozapine response, we have examined the hypothesis that polymorphisms in the 5-HT2A (HTR2A), and 5-HT2C (HTR2C) genes are involved in its variable response. A-1438 A-->G polymorphism in the putative promoter and a silent T-->C 102 substitution in HTR2A were in almost complete linkage disequilibrium, and neither was associated with response (T-->C. 102 allele: chi 2 = 0.02; 1 df, p = .90; genotype: chi 2 = 0.02, 2 df, p = .99). A his452tyr HTR2A polymorphism was found to be associated with clozapine response (his452tyr allele: chi 2 = 6.43, 1 df, p = .01 [p = .04, Bonferroni corrected]; genotype: chi 2 = 6.54, 2 df, p = .04 [p = .16, Bonferroni corrected]). No HTR2A haplotype was associated with response. Interethnic differences were observed in the frequencies of the cys23ser HTR2C polymorphism. This polymorphism was not significantly associated with response in either of the ethnic groups (Caucasian and African American genotype: chi 2 = 3.46, 2 df, p = .18; chi 2 = .31, 2 df, p = .86, respectively). Although replication is required, the overall results suggest that the his452tyr HTR2A polymorphism may be involved in clozapine response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629566     DOI: 10.1016/S0893-133X(98)00007-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

Review 1.  The challenges of psychopharmacogenetics.

Authors:  M Catalano
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

2.  Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Authors:  Takeshi Shiiki; Yukiya Hashimoto; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 3.  Receptor pharmacogenetics: relevance to CNS syndromes.

Authors:  Sanober Shaikh; Robert W Kerwin
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

Review 4.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 5.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

6.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

Review 7.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

8.  Genes and schizophrenia: from a Festschrift Seminar honoring William T. Carpenter Jr, MD.

Authors:  Anil K Malhotra
Journal:  Schizophr Bull       Date:  2013-10-10       Impact factor: 9.306

Review 9.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 10.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.